Ashley A Vo

Title(s)HS Clinical Professor, Pediatrics
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. Clin Transplant. 2022 08; 36(8):e14734. Pearl M, Weng PL, Chen L, Dokras A, Pizzo H, Garrison J, Butler C, Zhang J, Reed EF, Kim IK, Choi J, Haas M, Zhang X, Vo A, Chambers ET, Ettenger R, Jordan S, Puliyanda D. PMID: 35657013; PMCID: PMC9378624.
      View in: PubMed   Mentions:    Fields:    
    2. Intravenous immunoglobulin contains high-titer neutralizing IgG antibodies to SARS-CoV-2. Am J Transplant. 2022 May 05. Jordan SC, Berg A, Shin B, Vo A, Ammerman N, Zhang R. PMID: 35514147; PMCID: PMC9348077.
      View in: PubMed   Mentions:    Fields:    
    3. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients. Transpl Infect Dis. 2022 Apr; 24(2):e13813. Zhang R, Shin BH, Gadsden TM, Petrosyan A, Vo A, Ammerman N, Sethi S, Huang E, Peng A, Najjar R, Atienza J, Kim I, Jordan SC. PMID: 35202497; PMCID: PMC9115352.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    4. Viral-specific cytotoxic T-cell responses in HLA-sensitized kidney transplant patients maintained on everolimus and low-dose tacrolimus. Transpl Infect Dis. 2022 Apr; 24(2):e13805. Ge S, Chu M, Tang J, Kahwaji J, Karasyov A, Lovato D, Vo A, Choi J, Jordan SC, Zhang R, Toyoda M. PMID: 35213773.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. Kidney Int Rep. 2022 Apr; 7(4):720-731. Jordan SC, Ammerman N, Choi J, Huang E, Najjar R, Peng A, Sethi S, Sandhu R, Atienza J, Toyoda M, Ge S, Lim K, Gillespie M, Zhang X, Haas M, Vo A. PMID: 35497778; PMCID: PMC9039906.
      View in: PubMed   Mentions: 1  
    6. Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients. Transplantation. 2022 01 01; 106(1):e90-e91. Jordan SC, Shin BH, Gadsden TM, Chu M, Petrosyan A, Vo A, Ammerman N, Sethi S, Najjar R, Huang E, Peng A, Toyoda M, Kumar S, Zhang R. PMID: 34582140; PMCID: PMC8667672.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Am J Transplant. 2022 04; 22(4):1133-1144. Vo AA, Huang E, Ammerman N, Toyoda M, Ge S, Haas M, Zhang X, Peng A, Najjar R, Williamson S, Myers C, Sethi S, Lim K, Choi J, Gillespie M, Tang J, Jordan SC. PMID: 34910841.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Approach to Highly Sensitized Kidney Transplant Candidates and a Positive Crossmatch. Adv Chronic Kidney Dis. 2021 11; 28(6):587-595. Sethi S, Ammerman N, Vo A, Jordan SC. PMID: 35367027.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cell Mol Immunol. 2021 11; 18(11):2554-2556. Jordan SC, Shin BH, Gadsden TM, Chu M, Petrosyan A, Le CN, Zabner R, Oft J, Pedraza I, Cheng S, Vo A, Ammerman N, Plummer J, Ge S, Froch M, Berg A, Toyoda M, Zhang R. PMID: 34531555; PMCID: PMC8443898.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    10. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes). Transplantation. 2021 08 01; 105(8):1808-1817. Jordan SC, Legendre C, Desai NM, Lorant T, Bengtsson M, Lonze BE, Vo AA, Runström A, Laxmyr L, Sjöholm K, Schiött Å, Sonesson E, Wood K, Winstedt L, Kjellman C, Montgomery RA. PMID: 33093408; PMCID: PMC8294837.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    11. Infectious Complications in Tocilizumab-treated Kidney Transplant Recipients. Transplantation. 2021 08 01; 105(8):1818-1824. Sethi S, Peng A, Najjar R, Vo A, Jordan SC, Huang E. PMID: 33534530.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    12. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant. 2021 12; 21(12):3907-3918. Kjellman C, Maldonado AQ, Sjöholm K, Lonze BE, Montgomery RA, Runström A, Lorant T, Desai NM, Legendre C, Lundgren T, von Zur Mühlen B, Vo AA, Olsson H, Jordan SC. PMID: 34236770; PMCID: PMC9290474.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. J Am Soc Nephrol. 2021 02; 32(2):397-409. Reese PP, Aubert O, Naesens M, Huang E, Potluri V, Kuypers D, Bouquegneau A, Divard G, Raynaud M, Bouatou Y, Vo A, Glotz D, Legendre C, Lefaucheur C, Jordan S, Empana JP, Jouven X, Loupy A. PMID: 33323474; PMCID: PMC8054891.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    14. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. Clin Infect Dis. 2020 12 15; 71(12):3168-3173. Jordan SC, Zakowski P, Tran HP, Smith EA, Gaultier C, Marks G, Zabner R, Lowenstein H, Oft J, Bluen B, Le C, Shane R, Ammerman N, Vo A, Chen P, Kumar S, Toyoda M, Ge S, Huang E. PMID: 32575124; PMCID: PMC7337689.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    15. Interleukin-6: An Important Mediator of Allograft Injury. Transplantation. 2020 12; 104(12):2497-2506. Jordan SC, Ammerman N, Choi J, Kumar S, Huang E, Toyoda M, Kim I, Wu G, Vo A. PMID: 32235253.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    16. Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro. Transplantation. 2020 08; 104(8):1574-1579. Ge S, Chu M, Choi J, Louie S, Vo A, Jordan SC, Toyoda M. PMID: 32732834.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    17. Donor-derived Cell-free DNA Combined With Histology Improves Prediction of Estimated Glomerular Filtration Rate Over Time in Kidney Transplant Recipients Compared With Histology Alone. Transplant Direct. 2020 Aug; 6(8):e580. Huang E, Gillespie M, Ammerman N, Vo A, Lim K, Peng A, Najjar R, Sethi S, Jordan SC, Mirocha J, Haas M. PMID: 33134504; PMCID: PMC7581058.
      View in: PubMed   Mentions: 2  
    18. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients. Transplantation. 2020 07; 104(7):1500-1507. Sethi S, Najjar R, Peng A, Choi J, Lim K, Vo A, Jordan SC, Huang E. PMID: 31568398.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplant Proc. 2020 Nov; 52(9):2711-2714. Vaidya G, Czer LSC, Kobashigawa J, Kittleson M, Patel J, Chang D, Kransdorf E, Shikhare A, Tran H, Vo A, Ammerman N, Huang E, Zabner R, Jordan S. PMID: 32563584; PMCID: PMC7275980.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsPHPublic Health
    20. The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection. Am J Transplant. 2020 06; 20 Suppl 4:42-56. Jordan SC, Ammerman N, Choi J, Huang E, Peng A, Sethi S, Najjar R, Kim I, Toyoda M, Kumar S, Lim K, Vo A. PMID: 32538536.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    21. Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transplant. 2020 09; 20(9):2581-2588. Jordan SC, Kucher K, Bagger M, Hockey HU, Wagner K, Ammerman N, Vo A. PMID: 32301258.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    22. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection. Transplantation. 2020 04; 104(4):856-863. Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, Huang E, Jordan SC, Toyoda M. PMID: 31385933.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    23. Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics. Transplantation. 2020 01; 104(1):17-23. Jordan SC, Ammerman N, Vo A. PMID: 31397806.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    24. Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2020 01 07; 15(1):109-116. Huang E, Vo A, Choi J, Ammerman N, Lim K, Sethi S, Kim I, Kumar S, Najjar R, Peng A, Jordan SC. PMID: 31843975; PMCID: PMC6946080.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    25. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation. Transplantation. 2019 12; 103(12):2666-2674. Vo AA, Aubert O, Haas M, Huang E, Zhang X, Choi J, Peng A, Najjar R, Sethi S, Ammerman N, Lim K, Jordan SC. PMID: 30883456.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant. 2019 11; 19(11):3035-3045. Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D. PMID: 31257724; PMCID: PMC6899639.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    27. Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. Am J Transplant. 2019 06; 19(6):1663-1670. Huang E, Sethi S, Peng A, Najjar R, Mirocha J, Haas M, Vo A, Jordan SC. PMID: 30725531.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    28. Allocation of the Highest Quality Kidneys and Transplant Outcomes Under the New Kidney Allocation System. Am J Kidney Dis. 2019 05; 73(5):605-614. Sethi S, Najjar R, Peng A, Mirocha J, Vo A, Bunnapradist S, Jordan SC, Huang E. PMID: 30929853.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection. Transplantation. 2019 02; 103(2):262-272. Jordan SC, Ammerman N, Choi J, Huang E, Peng A, Sethi S, Najjar R, Toyoda M, Lim K, Louie S, Vo A. PMID: 30247320.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy. Am J Transplant. 2019 02; 19(2):381-390. Pinelli DF, Zachary AA, Friedewald JJ, Gjertson DW, Evans MA, Chatroop EN, Leffell MS, Vo AA, Jordan SC, Montgomery RA, Tambur AR. PMID: 29981209.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    31. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients. Am J Transplant. 2018 12; 18(12):2955-2964. Jordan SC, Choi J, Aubert O, Haas M, Loupy A, Huang E, Peng A, Kim I, Louie S, Ammerman N, Najjar R, Puliyanda D, Vo A. PMID: 29637714.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    32. Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection. Transplantation. 2017 10; 101(10):2419-2428. Zhang H, Huang E, Kahwaji J, Nast CC, Li P, Mirocha J, Thomas DL, Ge S, Vo AA, Jordan SC, Toyoda M. PMID: 28557957.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    33. Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients. Pediatr Transplant. 2017 Dec; 21(8). Kim IK, Choi J, Vo A, Kang A, Steggerda J, Louie S, Haas M, Mirocha J, Cohen JL, Pizzo H, Kamil ES, Jordan SC, Puliyanda D. PMID: 28929636.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017 08 03; 377(5):442-453. Jordan SC, Lorant T, Choi J, Kjellman C, Winstedt L, Bengtsson M, Zhang X, Eich T, Toyoda M, Eriksson BM, Ge S, Peng A, Järnum S, Wood KJ, Lundgren T, Wennberg L, Bäckman L, Larsson E, Villicana R, Kahwaji J, Louie S, Kang A, Haas M, Nast C, Vo A, Tufveson G. PMID: 28767349.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    35. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients. Transplantation. 2017 07; 101(7):1720-1726. Ge S, Karasyov A, Sinha A, Petrosyan A, Lovato D, Thomas DL, Vo A, Jordan SC, Toyoda M. PMID: 27841845.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    36. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients. Transplantation. 2017 04; 101(4):883-889. Kim IK, Choi J, Vo AA, Kang A, Patel M, Toyoda M, Mirocha J, Kamil ES, Cohen JL, Louie S, Galera O, Jordan SC, Puliyanda DP. PMID: 27495773; PMCID: PMC7228615.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    37. Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. J Immunol Res. 2017; 2017:5672523. Toyoda M, Shin BH, Ge S, Mirocha J, Thomas D, Chu M, Rodriguez E, Chao C, Petrosyan A, Galera OA, Vo A, Choi J, Peng A, Kahwaji J, Jordan SC. PMID: 28265581; PMCID: PMC5317146.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    38. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. Kidney Int. 2017 03; 91(3):729-737. Haas M, Mirocha J, Reinsmoen NL, Vo AA, Choi J, Kahwaji JM, Peng A, Villicana R, Jordan SC. PMID: 28104301.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    39. Desensitization: Overcoming the Immunologic Barriers to Transplantation. J Immunol Res. 2017; 2017:6804678. Sethi S, Choi J, Toyoda M, Vo A, Peng A, Jordan SC. PMID: 28127571; PMCID: PMC5239985.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    40. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. Transplantation. 2017 Jan; 101(1):32-44. Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, Vo A. PMID: 27547870.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCells
    41. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017 Mar; 139(3S):S1-S46. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Stiehm ER, Vo AA, Ballow M. PMID: 28041678.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansAnimals
    42. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Int. 2016 Dec; 29(12):1276-1285. Kahwaji J, Jordan SC, Najjar R, Wongsaroj P, Choi J, Peng A, Villicana R, Vo A. PMID: 27529314.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    43. Risk factors associated with the development of histocompatibility leukocyte antigen sensitization. Curr Opin Organ Transplant. 2016 08; 21(4):447-52. Jordan SC, Choi J, Kim I, Vo A, Peng A, Kahwaji J. PMID: 27258577.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Transplantation. 2015 Nov; 99(11):2356-63. Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J, Toyoda M, Ge S, Haas M, Puliyanda D, Reinsmoen N, Peng A, Villicana R, Jordan SC. PMID: 26018350.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    45. Modern approaches to incompatible kidney transplantation. World J Nephrol. 2015 Jul 06; 4(3):354-62. Wongsaroj P, Kahwaji J, Vo A, Jordan SC. PMID: 26167458; PMCID: PMC4491925.
      View in: PubMed   Mentions: 7  
    46. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. Transplantation. 2015 Jul; 99(7):1423-30. Vo AA, Sinha A, Haas M, Choi J, Mirocha J, Kahwaji J, Peng A, Villicana R, Jordan SC. PMID: 25606792.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    47. Kidney transplantation in highly sensitized patients. Br Med Bull. 2015 Jun; 114(1):113-25. Jordan SC, Choi J, Vo A. PMID: 25935575.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    48. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation. 2015 Feb; 99(2):299-308. Vo AA, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J, Peng A, Villicana R, Puliyanda D, Reinsmoen N, Haas M, Jordan SC. PMID: 25606785.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    49. Immunologic and Infectious Complications in Highly Sensitized Patients Post-Kidney Transplantation. Clin Transpl. 2015; 31:265-273. Kahwaji J, Choi J, Vo A, Jordan SC. PMID: 28514588.
      View in: PubMed   Mentions: 1     Fields:    
    50. Strategies to Improve Novel Drug Development in Kidney Transplantation Through the Clinical Trials Process. Clin Transpl. 2015; 31:163-172. Jordan SC, Choi J, Vo A. PMID: 28514578.
      View in: PubMed   Mentions:    Fields:    
    51. Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy. 2015; 7(4):377-98. Jordan SC, Choi J, Vo A. PMID: 25917629.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    52. Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches. Curr Opin Organ Transplant. 2014 Dec; 19(6):591-7. Jordan SC, Vo AA. PMID: 25304815.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    53. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014 Aug 15; 98(3):312-9. Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, Ge S, Toyoda M, Kahwaji J, Peng A, Villicana R, Jordan SC. PMID: 24770617.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    54. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab. Transplantation. 2014 Apr 15; 97(7):755-61. Barbosa D, Kahwaji J, Puliyanda D, Mirocha J, Reinsmoen N, Lai CH, Villicana R, Peng A, Jordan SC, Vo A, Toyoda M. PMID: 24686425.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    55. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clin Transplant. 2014 May; 28(5):546-53. Kahwaji J, Najjar R, Kancherla D, Villicana R, Peng A, Jordan S, Vo A, Haas M. PMID: 24579925.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    56. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. Transplantation. 2014 Feb 15; 97(3):294-300. Shin BH, Ge S, Mirocha J, Karasyov A, Vo A, Jordan SC, Toyoda M. PMID: 24342979.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    57. Defining the benefits of desensitization therapy. Transplantation. 2013 Mar 27; 95(6):e31-2. Jordan SC, Vo A, Lai CH, Reinsmoen N. PMID: 23507651.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    58. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation. 2013 Mar 27; 95(6):852-8. Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, Villicana R, Mackowiak J, Jordan SC. PMID: 23511212.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    59. Evolving concepts in desensitization. Clin Transpl. 2013; 285-92. Jordan SC, Vo AA. PMID: 25095520.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    60. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med. 2012 Apr; 13(71):267-73. Reinsmoen NL, Lai CH, Vo A, Jordan SC. PMID: 22541614.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    61. Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant. Am J Kidney Dis. 2012 Jun; 59(6):758-60. Jordan SC, Vo AA. PMID: 22464877.
      View in: PubMed   Mentions: 1     Fields:    
    62. Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients. Discov Med. 2012 Mar; 13(70):235-45. Jordan SC, Reinsmoen N, Lai CH, Vo A. PMID: 22463800.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    63. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol. 2011 Dec; 6(12):2894-900. Kahwaji J, Sinha A, Toyoda M, Ge S, Reinsmoen N, Cao K, Lai CH, Villicana R, Peng A, Jordan S, Vo A. PMID: 22157713; PMCID: PMC3255382.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    64. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant. 2011 Aug; 16(4):416-24. Jordan SC, Kahwaji J, Toyoda M, Vo A. PMID: 21666479.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    65. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation. 2011 Jul 15; 92(1):48-53. Lai CH, Cao K, Ong G, Naim M, Wang Q, Mirocha J, Vo A, Jordan SC, Reinsmoen NL. PMID: 21562450.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    66. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol. 2011 May; 7(3):341-8. Jordan SC, Toyoda M, Vo AA. PMID: 21595600.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    67. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation. 2010 Dec 27; 90(12):1473-7. Reinsmoen NL, Lai CH, Heidecke H, Haas M, Cao K, Ong G, Naim M, Wang Q, Mirocha J, Kahwaji J, Vo AA, Jordan SC, Dragun D. PMID: 21030904.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    68. Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transpl Immunol. 2011 Apr 15; 24(3):142-8. Ge S, Pao A, Vo A, Deer N, Karasyov A, Petrosyan A, Kahwaji J, Lukovsky M, Chai NN, Aguiluz A, Mirocha J, Jordan SC, Toyoda M. PMID: 21122815.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    69. Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clin Exp Nephrol. 2011 Feb; 15(1):164-70. Sinha A, Nast CC, Hristea I, Vo AA, Jordan SC. PMID: 21107633.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    70. ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation? Expert Rev Clin Immunol. 2010 Nov; 6(6):893-900. Kahwaji J, Vo AA, Jordan SC. PMID: 20979554.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    71. Cellular allo reactivity against paternal HLA antigens in normal multiparous females as detected by intracellular cytokine flow cytometry remains elevated over years despite diminution of anti-HLA antibody levels. Transpl Immunol. 2010 Jul; 23(3):133-40. Toyoda M, Ge S, Pao A, Vo A, Deer N, Aguiluz A, Karasyov A, Jordan SC. PMID: 20472061.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    72. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010 May 15; 89(9):1095-102. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC. PMID: 20110854.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    73. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol. 2010 Oct; 25(10):2035-45; quiz 2045-8. Jordan SC, Reinsmoen N, Peng A, Lai CH, Cao K, Villicana R, Toyoda M, Kahwaji J, Vo AA. PMID: 20077121; PMCID: PMC2923704.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    74. Intracellular IFNgamma production in CD3 negative cells exposed to allo-antigens is an indicator of prior sensitization. Transpl Immunol. 2010 Feb; 22(3-4):121-7. Toyoda M, Pao A, Vo A, Lukovsky M, Radha R, Sado T, Ge S, Reinsmoen N, Chai NN, Baden L, Petrosyan A, Skinner E, Mirocha J, Jordan SC. PMID: 19944759.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    75. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol. 2009 Dec; 4(12):1993-7. Kahwaji J, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A, Chang R, Jordan SC, Vo AA. PMID: 19833910; PMCID: PMC2798878.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    76. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation. 2009 Jul 15; 88(1):1-6. Jordan SC, Toyoda M, Vo AA. PMID: 19584672.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    77. Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts. J Clin Apher. 2009; 24(4):155-60. Sivakumaran P, Vo AA, Villicana R, Peng A, Jordan SC, Pepkowitz SH, Klapper EB. PMID: 19658162.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    78. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Contrib Nephrol. 2009; 162:13-26. Jordan SC, Peng A, Vo AA. PMID: 19001810.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation. 2008 Sep 27; 86(6):820-5. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, Wang Q, Jordan SC. PMID: 18813107.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    80. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008 Jul 17; 359(3):242-51. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. PMID: 18635429.
      View in: PubMed   Mentions: 137     Fields:    Translation:HumansCTClinical Trials
    81. Anti-glomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol. 2008 Mar; 4(3):167-71. Wechsler E, Yang T, Jordan SC, Vo A, Nast CC. PMID: 18212779.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    82. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant. 2008 Jan; 23(1):377-80. Yang T, Nast CC, Vo A, Jordan SC. PMID: 17981884.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    83. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant. 2008 Jan; 8(1):144-9. Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, Reinsmoen N, Jordan SC. PMID: 17973966.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    84. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant. 2006 Oct; 6(10):2384-90. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC. PMID: 16869794.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    85. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol. 2006 Jul; 1(4):844-52. Vo AA, Cam V, Toyoda M, Puliyanda DP, Lukovsky M, Bunnapradist S, Peng A, Yang K, Jordan SC. PMID: 17699296.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    86. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc. 2006; 117:199-211; discussion 211. Jordan SC, Vo A, Tyan D, Toyota M. PMID: 18528474; PMCID: PMC1500934.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    87. Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation. 2005 Jul 27; 80(2):198-205. Toyoda M, Puliyanda DP, Amet N, Baden L, Cam V, Radha R, Pao A, Vo A, Bunnapradist S, Moudgil A, Jordan SC. PMID: 16041264.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    88. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant. 2005 Jun; 9(3):408-15. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. PMID: 15910400.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    89. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transplant. 2005 Apr; 9(2):155-61. Jordan SC, Vo AA, Toyoda M, Tyan D, Nast CC. PMID: 15787786.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    90. Cyclosporine-sparing effects of daclizumab in renal allograft recipients. Am J Health Syst Pharm. 2005 Feb 15; 62(4):391-6. Ingle GR, Moudgil A, Vo A, Jordan SC. PMID: 15745891.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    91. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004 Dec; 15(12):3256-62. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J. PMID: 15579530.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    92. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl. 2003; 193-8. Jordan SC, Vo AA, Nast CC, Tyan D. PMID: 15387111.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    93. Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation. Transplantation. 2002 Dec 15; 74(11):1648-51. Bunnapradist S, Vo A, Toyoda M, Alsabeh R, Lockhart C, Puliyanda D, Jordan SC. PMID: 12490805.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    94. Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction. Am J Transplant. 2002 Aug; 2(7):671-3. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Kamil E. PMID: 12201370.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    95. Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. Am J Transplant. 2002 May; 2(5):425-8. Barsoum NR, Bunnapradist S, Mougdil A, Toyoda M, Vo A, Jordan SC. PMID: 12123207.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    Ashley's Networks
    Concepts (266)
    Derived automatically from this person's publications.
    Co-Authors (11)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department